Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article from Managed Healthcare Executive® referenced an article published on AJMC.com, the website of The American Journal of Managed Care® (AJMC®). The article, “Deuruxolitinib Demonstrates Efficacy, Tolerability in Patients With Moderate to Severe AA,” highlighted results from a poster presented at the 2024 American Academy of Dermatology Annual Meeting, which found that the Janus kinase inhibitor deuruxolitinib resulted in hair regrowth in patients with moderate to severe alopecia areata, with efficacy and tolerability.
An article from Pharmacy Times® referenced a resource published by AJMC’s sister site, The Center for Biosimilars®. The page, “The Center for Biosimilars: Biosimilars Approvals,” lists all 49 approved biosimilars in the US, including the name of each drug and the conditions it treats.
Liso-Cel Improves Outcomes in R/R CLL/SLL Following 2 or More Lines of Therapy
June 26th 2025Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen